scispace - formally typeset
B

Bruce Patterson

Researcher at Ontario Institute for Cancer Research

Publications -  10
Citations -  1291

Bruce Patterson is an academic researcher from Ontario Institute for Cancer Research. The author has contributed to research in topics: Lymphoma & Reed–Sternberg cell. The author has an hindex of 7, co-authored 10 publications receiving 1231 citations.

Papers
More filters
Journal ArticleDOI

Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function

TL;DR: Lymphocyte-specific interferon regulatory factor (LSIRF) (now called IRF4) is a transcription factor expressed only in lymphocytes that is essential for the function and homeostasis of both mature B and mature T lymphocytes.
Journal ArticleDOI

Interleukin 13 Is Secreted by and Stimulates the Growth of Hodgkin and Reed-Sternberg Cells

TL;DR: The expression of 950 genes in Hodgkin's disease (HD) is investigated by analyzing differential mRNA expression using microarrays and suggests that IL-13 plays an important role in the stimulation of H/RS cell growth, possibly by an autocrine mechanism.
Journal ArticleDOI

Isolated chloroma: the effect of early antileukemic therapy.

TL;DR: No clear evidence has shown that early treatment of isolated chloroma with chemotherapy alters progression to leukemia or prolongs survival, and to address this issue, an analysis of a comprehensive retrospective review of the medical literature was conducted.
Journal Article

In vivo evidence that caspase-3 is required for Fas-mediated apoptosis of hepatocytes.

TL;DR: Novel in vivo evidence is provided that caspase-3, conventionally known for its downstream effector function in apoptosis, also modifies Bcl-2 and other upstream proteins involved in the regulation of Fas-mediated apoptosis.
Journal ArticleDOI

Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia after Treatment with Recombinant Erythropoietin Products: Recommendations for Minimization of Risk

TL;DR: There is currently no evidence that other products are safer than Ab+ PRCA, and the subcutaneous administration of HSA-containing Eprex is riskier than intravenous Epogen and intravenous HSA/subcutaneous NeoRecormon is riskiest than intravenously Epogen.